Biologic Therapeutics for Type 2 Asthma
  • CME

Here’s why targeted biologic therapies are a great advance for treating type 2 asthma.
Eileen Wang, MD, MPH
Physicians: maximum of 0.25 AMA PRA Category 1 Credits
Released: September 21, 2020 Expiration: September 20, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Describe the indications and safety of novel targeted biologic agents that have been recently approved as add-on therapy for type 2 asthma

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

This activity is supported by educational grants from
Novartis Pharmaceuticals Corporation
Sanofi Genzyme and Regeneron Pharmaceuticals

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Eileen Wang, MD, MPH

Assistant Professor
Division of Allergy and Immunology
Department of Medicine
National Jewish Health
University of Colorado School of Medicine
Denver and Aurora, Colorado

Eileen Wang, MD, MPH has disclosed that she has received fees for non-CME/CE services from AstraZeneca and funds for research support from Genentech and GlaxoSmithKline.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc has no relevant conflicts of interest to report.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for allergists, immunologists, pulmonologists, primary care physicians, physician assistants, and other healthcare professionals who care for patients with severe eosinophilic asthma.

Goal

The goal of this activity is to improve the competence and performance of learners in diagnosing, assessing, and treating patients with severe eosinophilic asthma.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from September 21, 2020, through September 20, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 50% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Expert commentaries on managing severe asthma and best practice with targeted biologic therapies for type 2 asthma

Eileen Wang, MD, MPH Michael E. Wechsler, MD, MMSc Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: October 7, 2020 Expired: October 6, 2021

Concise CCO expert commentary on assessment and treatment choice for patients not controlled on traditional asthma therapies

Michael E. Wechsler, MD, MMSc Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: August 24, 2020 Expired: August 23, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue